Pharvaris Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

April 5, 2023

https://www.globenewswire.com/news-release/2023/04/05/2641510/0/en/Pharvaris-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html

ZUG, Switzerland, April 05, 2023 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq:PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the fourth quarter and year ended December 31, 2022 and provided a business update.

Read more at globenewswire.com

Related news for (PHVS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.